R-Spondins are a small family of signaling proteins that act as volume knobs for one of the body’s most important communication networks, the Wnt pathway, which guides everything from how stem cells renew themselves to how embryos take shape. Over the past decade, research has revealed that these proteins do far more than amplify a single signal. They help the liver organize its internal geography, influence whether an embryo develops ovaries or testes, keep the intestinal lining replenishing itself, and, when their genes are rearranged or overproduced, can drive certain cancers. Understanding how R-Spondins operate has opened new doors for targeted therapies and even raised unexpected possibilities like treating hair loss and organ fibrosis.
What R-Spondins Are and How They Signal
Vertebrates carry four R-Spondin genes (RSPO1 through RSPO4), each encoding a secreted protein of roughly 35 kilodaltons. Despite their modest size, these proteins pack a specific structural toolkit: two furin-like repeats near the front end that are responsible for boosting Wnt signaling, and a thrombospondin domain toward the back end that can latch onto sugar-rich molecules on cell surfaces.1PubMed Central. The R-spondin protein family The family appears to be exclusive to vertebrates; computational studies have found no equivalent domains in invertebrates like fruit flies or roundworms.2PubMed Central. Computational Biophysical, Biochemical, and Evolutionary Signature of Human R-Spondin Family Proteins, the Member of Canonical Wnt/β-Catenin Signaling Pathway
The classic understanding of R-Spondin signaling centered on a receptor called LGR (specifically LGR4, 5, and 6). R-Spondins bind LGR on a cell’s surface, which triggers the removal of two enzymes, ZNRF3 and RNF43, that normally chew up Wnt receptors. With those enzymes cleared away, Wnt receptors accumulate on the cell surface, and the cell becomes more sensitive to Wnt signals. Think of it as removing the brakes on Wnt reception rather than pressing the accelerator directly.
What surprised researchers was the discovery that R-Spondins can boost Wnt signaling even when LGR receptors are completely absent. In cells engineered to lack all three LGRs, R-Spondin 3 still potentiated Wnt activity by binding to heparan sulfate proteoglycans (HSPGs), sugar-coated proteins found on virtually every cell surface.3eLife. R-spondins can potentiate WNT signaling without LGRs Follow-up work confirmed that the thrombospondin domain, once considered unimportant for Wnt boosting, is essential for this alternative route. In fact, replacing the HSPG-binding region of RSPO3 with an antibody fragment that grabs heparan sulfate chains preserved full signaling activity in both cultured cells and intestinal organoids.4eLife. R-spondins engage heparan sulfate proteoglycans to potentiate WNT signaling This means R-Spondins have two parallel entry points into cells: one through LGRs and one through HSPGs. Both converge on the same downstream effect of suppressing ZNRF3/RNF43 and letting Wnt receptors persist, but they use different docking stations to get there.
Keeping Tissues Running Smoothly
Wnt signaling is one of the master regulators of stem cell behavior, so it makes sense that R-Spondins show up wherever tissues need constant renewal or precise spatial organization. Some of the clearest examples come from the gut, the liver, bone, and even taste buds.
In the intestine, the lining replaces itself roughly every five days, powered by stem cells nestled in tiny pockets called crypts. R-Spondin proteins, especially RSPO3, are secreted by stromal cells surrounding those crypts and help set the size of the stem cell pool by sustaining Wnt signaling in stem cells.5Nature Communications. R-spondin 3 promotes stem cell recovery and epithelial regeneration in the colon When RSPO3 is depleted, the gut becomes more vulnerable to chemical injury, and recovery slows.
The liver tells a different but equally striking story. Hepatocytes near the central vein of a liver lobule perform different metabolic tasks than those at the periphery, a phenomenon called metabolic zonation. RSPO3, produced by the endothelial cells lining the central vein, turns out to be a key architect of that zonation. Deleting RSPO3 in mice disrupts the central-vein gene program, and artificially introducing a related family member, RSPO1, in the wrong location can reprogram peripheral hepatocytes toward a central-vein identity.6Cell Reports. The Angiocrine Factor Rspondin3 Is a Key Determinant of Liver Zonation This makes R-Spondin signaling not just a stem cell regulator but also a geographic instruction manual for liver function.
Bone adds a twist that defies simple “more is better” logic. In the limb skeleton of mice, reducing RSPO3 actually increased bone mass by enhancing bone-forming cell activity. The mechanism involves a chain reaction: RSPO3 deficiency activates a kinase called Erk, which in turn stabilizes the downstream Wnt effector and promotes bone-building cell production.7eLife. R-spondin 3 deletion induces Erk phosphorylation to enhance Wnt signaling and promote bone formation in the appendicular skeleton This counterintuitive finding shows that R-Spondins do not universally amplify Wnt in every tissue in the same way; context shapes the outcome.
Even taste perception depends on R-Spondins. Taste bud cells turn over regularly, and organoid cultures show that without R-Spondin in the growth medium, differentiated taste cells simply do not form.8PubMed Central. R-spondin substitutes for neuronal input for taste cell regeneration in adult mice R-Spondin can even substitute for neuronal input that normally drives taste cell renewal, hinting at therapeutic applications for people who lose taste sensation after nerve injury or radiation therapy.
Sexual Development and the Ovarian Pathway
One of the more dramatic roles for an R-Spondin involves sex determination. For decades, female development in mammals was viewed as the default state in the absence of the male-determining gene SRY. R-Spondin 1 overturned that assumption. In humans, loss-of-function mutations in RSPO1 cause genetically female (XX) individuals to develop testes, pointing to RSPO1 as an active driver of ovary formation rather than a passive bystander.9PubMed Central. Cloning and expression of R-Spondin1 in different vertebrates suggests a conserved role in ovarian development
Studies in mouse, chicken, and turtle embryos all find that RSPO1 expression is higher in developing ovaries than testes right around the time sexual differentiation begins, suggesting an ancient, conserved role across vertebrates with very different sex-determination systems.9PubMed Central. Cloning and expression of R-Spondin1 in different vertebrates suggests a conserved role in ovarian development In human fetal gonads between six and nine weeks after conception, RSPO1 levels climb steadily in the ovary while remaining low and flat in the testis.10PLOS ONE. Human RSPO1/R-spondin1 Is Expressed during Early Ovary Development and Augments β-Catenin Signaling
Mouse knockout experiments fill in the mechanism. Female mice lacking RSPO1 develop masculinized features: male-type blood vessels in the gonad, ectopic testosterone production, and loss of fetal egg cells. These defects mirror what happens in mice missing WNT4, and molecular analysis confirmed that RSPO1 works by boosting WNT4 signaling in the developing ovary.11Human Molecular Genetics. R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling The sex reversal is partial in mice but more complete in humans, suggesting species-level differences in how much redundancy backs up the ovarian program.
When R-Spondin Signaling Goes Wrong in Cancer
Given how potently R-Spondins amplify Wnt signaling, it follows that genetic mishaps involving these proteins can fuel tumor growth. The clearest example is in colorectal cancer, where chromosomal rearrangements fuse R-Spondin genes to strong promoters, causing the cell to pump out R-Spondin protein nonstop. In a large analysis, about 3% of colorectal cancers carried RSPO fusions, predominantly PTPRK-RSPO3 fusions (24 of 29 cases) alongside a smaller number of EIF3E-RSPO2 fusions.12PubMed Central. Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer These fusions tend to occur in tumors that lack the more common APC mutations, suggesting they represent an alternative route to Wnt pathway activation.
R-Spondin disruption does not always mean overproduction, though. The enzymes ZNRF3 and RNF43, which R-Spondins normally regulate, are themselves frequently mutated in cancers. When RNF43 carries inactivating frameshift mutations, tumor cells become dependent on both Wnt ligands and R-Spondin for growth, because they need R-Spondin to suppress the remaining functional copy of ZNRF3.13PubMed Central. Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer This dependency creates a potential vulnerability: if you can block R-Spondin or upstream Wnt signals, these tumors may lose their growth advantage. Genetic alterations in RNF43, ZNRF3, RSPO2, and RSPO3 have shown early promise as predictive markers for response to upstream Wnt inhibitors in preclinical models.14PubMed Central. Control of Wnt Receptor Turnover by R-spondin-ZNRF3/RNF43 Signaling Module and Its Dysregulation in Cancer
In prostate cancer, the picture is more nuanced. Overexpression of RSPO2 in cell lines switches on programs linked to epithelial-mesenchymal transition, a process that makes cancer cells more mobile and invasive.15PubMed Central. Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer Meanwhile, RSPO3 tells the opposite story in the same organ: lower RSPO3 levels correlate with worse outcomes. Patients with reduced RSPO3 expression have lower relapse-free survival, and knocking down RSPO3 in lab models increases invasiveness and metastatic potential, apparently by triggering that same epithelial-mesenchymal transition from a different angle.16PubMed Central. RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer The fact that two members of the same protein family can push prostate cancer in opposite directions underscores how context-dependent R-Spondin biology really is.
R-Spondins As Biomarkers
Beyond their role as drivers of disease, R-Spondin expression levels may help predict how a cancer will behave. In lung cancer, RSPO1, RSPO2, and RSPO3 are all expressed at lower levels in tumors compared to normal lung tissue, and higher expression of each is associated with better survival in patients with lung adenocarcinoma.17PubMed Central. R-spondin family members as novel biomarkers and prognostic factors in lung cancer This pattern, where reduced R-Spondin levels signal more aggressive disease, echoes the prostate cancer findings for RSPO3 and raises the possibility that certain R-Spondins act as tumor suppressors in some tissues while acting as oncogenes in others.
R-Spondins also play a role in the blood supply tumors need to grow. Deleting RSPO3 specifically in endothelial cells disrupts vascular remodeling, leading to increased cell death in blood vessel walls and reduced blood vessel density in both developing tissues and tumors.18PubMed. Endothelial RSPO3 Controls Vascular Stability and Pruning through Non-canonical WNT/Ca(2+)/NFAT Signaling This finding connects R-Spondin biology to the tumor microenvironment and suggests that targeting RSPO3 might starve tumors of their blood supply in addition to dampening Wnt signaling directly.
Therapeutic Strategies Targeting R-Spondins
The most advanced therapeutic approach involves monoclonal antibodies designed to neutralize specific R-Spondin proteins. In preclinical testing, anti-RSPO antibodies inhibited tumor growth across multiple human tumor types transplanted into mice, including colorectal cancer, non-small-cell lung cancer, and ovarian cancer models. The antibodies worked both as single agents and in combination with chemotherapy, and they also reduced the ability of cancer cells to re-establish tumors when transplanted serially, suggesting an effect on cancer stem cells.19PubMed. Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types Gene expression analysis showed that treatment strongly suppressed Wnt target genes associated with both cancer and normal stem cells.20Cancer Research. Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types
A major concern with any therapy that dials down Wnt signaling is collateral damage to healthy tissues that depend on it. Bone is a prime example. Mice treated with two different small-molecule Wnt inhibitors (which block Wnt production upstream of R-Spondins) lost bone volume and density within four weeks, accompanied by a surge of fat cells in the bone marrow.21PubMed Central. Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy This side effect echoes the bone findings described earlier, where RSPO3 loss paradoxically increased bone mass in limb bones. The difference likely reflects the distinction between partial, tissue-specific R-Spondin modulation and the systemic Wnt shutdown caused by broad inhibitors. Strategies that target specific R-Spondin family members or act only in the tumor microenvironment may avoid much of this toxicity, but that remains to be proven in human trials.
Fibrosis Across Multiple Organs
R-Spondin research has expanded well beyond cancer into chronic fibrotic diseases, where organs gradually replace functional tissue with scar-like material. RSPO3 levels are markedly elevated in the active lesions of fibrotic tissues in both mouse models and human patients with conditions like idiopathic pulmonary fibrosis and nonalcoholic steatohepatitis, the inflammatory liver disease often linked to obesity. An anti-RSPO3 antibody called OMP-131R10 reduced fibrosis when administered therapeutically in mouse models of liver, lung, and skin fibrosis.22PubMed Central. Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs The fact that a single R-Spondin target showed effects across three different organs suggests that RSPO3-driven Wnt activation may be a shared feature of fibrotic progression rather than something unique to one tissue.
This cross-organ relevance is part of what makes R-Spondin biology so appealing as a therapeutic target. Fibrotic diseases collectively affect millions of people and have few effective treatments. If anti-RSPO3 approaches translate from mice to humans, they could address a broad unmet need.
Hair Follicle Regeneration
On a lighter but commercially significant note, R-Spondins have attracted attention for their ability to wake up dormant hair follicles. Hair growth cycles between active growth (anagen), regression (catagen), and rest (telogen), and the transition from rest to growth depends heavily on Wnt signaling in hair follicle stem cells. In mice, subcutaneous injection of recombinant RSPO1 activated hair follicle stem cells, increased the hair-covered area, and produced follicles with greater diameter and length.23PubMed Central. Novel recombinant R-spondin1 promotes hair regeneration by targeting the Wnt/β-catenin signaling pathway RSPO2 injection achieved a related effect: it activated LGR5-positive stem cells in the follicle, suppressed the onset of catagen, and extended the active growth phase so that hair shafts grew longer.24PubMed. Activating Hair Follicle Stem Cells via R-spondin2 to Stimulate Hair Growth
Whether these findings translate to humans remains an open question. Mouse hair cycling is far more synchronized and experimentally tractable than human hair growth, and delivering a protein to human scalp follicles at the right dose without systemic Wnt effects is a nontrivial engineering problem. Still, the specificity of R-Spondins, which amplify existing Wnt signals rather than flooding the system with new ones, makes them an attractive candidate for topical or localized delivery compared to broader Wnt agonists. Several biotech efforts are exploring this space, though none have reached late-stage clinical trials as of this writing.
Why Different Family Members Do Different Things
A recurring theme across all of these tissues is that the four R-Spondins are not interchangeable. RSPO1 drives ovary formation. RSPO3 patterns the liver and maintains gut stem cells. RSPO2 overexpression promotes invasiveness in prostate cancer cells while RSPO3 loss does the same thing through a distinct pathway. This functional specificity likely arises from differences in where each family member is expressed, which cells produce it, what local co-receptors are available, and subtle structural differences in how each protein interacts with LGRs versus HSPGs.
The discovery of the HSPG-dependent signaling mode adds another layer of complexity. In tissues rich in LGR-expressing stem cells, R-Spondins probably act primarily through the LGR route. In tissues where LGR expression is low, the HSPG route may dominate. And in tumors, where both receptor populations can shift dramatically, the balance between these two modes could determine whether an R-Spondin-targeting therapy works or fails. Researchers are still mapping out which mode matters most in each clinical context, and until that map is more complete, therapeutic design will involve some educated guesswork about which arm of signaling to target and where.